# An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT00337285** · PHASE3 · COMPLETED · sponsor: **New River Pharmaceuticals** · enrollment: 349 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Attention Deficit Disorders With Hyperactivity
- Attention Deficit Hyperactivity Disorders

## Interventions

- **DRUG:** Vyvanse (lisdexamfetamine dimesylate), NRP104

## Key facts

- **NCT ID:** NCT00337285
- **Lead sponsor:** New River Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-11
- **Final completion:** 2008-06
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2012-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337285, "An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00337285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*